Mitochondria and cardiovascular diseases—from pathophysiology to treatment

Gerasimos Siasos(Brigham and Women's Hospital), Vasiliki Tsigkou(National and Kapodistrian University of Athens), Marinos Kosmopoulos(National and Kapodistrian University of Athens), Dimosthenis Theodosiadis(National and Kapodistrian University of Athens), Spyridon Simantiris(National and Kapodistrian University of Athens), Nikoletta Maria Tagkou(National and Kapodistrian University of Athens), Athina Tsimpiktsioglou(National and Kapodistrian University of Athens), Panagiota K. Stampouloglou(National and Kapodistrian University of Athens), Evangelos Oikonomou(National and Kapodistrian University of Athens), Konstantinos Mourouzis(National and Kapodistrian University of Athens), Αnastassios Philippou(National and Kapodistrian University of Athens), Manolis Vavuranakis(National and Kapodistrian University of Athens), Christodoulos Stefanadis(Yale University), Dimitris Tousoulis(National and Kapodistrian University of Athens), Athanasios G. Papavassiliou(National and Kapodistrian University of Athens)
Annals of Translational Medicine
June 1, 2018
Cited by 243Open Access
Full Text

Abstract

Mitochondria are the source of cellular energy production and are present in different types of cells. However, their function is especially important for the heart due to the high demands in energy which is achieved through oxidative phosphorylation. Mitochondria form large networks which regulate metabolism and the optimal function is achieved through the balance between mitochondrial fusion and mitochondrial fission. Moreover, mitochondrial function is upon quality control via the process of mitophagy which removes the damaged organelles. Mitochondrial dysfunction is associated with the development of numerous cardiac diseases such as atherosclerosis, ischemia-reperfusion (I/R) injury, hypertension, diabetes, cardiac hypertrophy and heart failure (HF), due to the uncontrolled production of reactive oxygen species (ROS). Therefore, early control of mitochondrial dysfunction is a crucial step in the therapy of cardiac diseases. A number of anti-oxidant molecules and medications have been used but the results are inconsistent among the studies. Eventually, the aim of future research is to design molecules which selectively target mitochondrial dysfunction and restore the capacity of cellular anti-oxidant enzymes.


Related Papers

No related papers found

Powered by citation graph analysis